In this video, Rod discusses delta-8 THC, CBD and cannabis in Europe and Mexico, the role of international treaties in cannabis reform, California’s Proposition 65, and the FDA’s position on CBD, among other cannabis issues.
Category: International Commerce
Listen to Rod and other industry experts discuss the dichotomy between patenting psychedelics compounds and promoting free and open research, the complexities of South American cannabis in Europe, the 12,000 year old relationship between humans and psychedelics, a side by side comparison of two hallucinogenic substances, and how well various cannabinoids permeate the skin.
A UN committee voted today on six proposals regarding cannabis. In addition to voting to remove cannabis from schedule IV, the Committee voted on five other related proposals.
I recently had a wide-ranging discussion about cannabinoids, hemp, and marijuana with Kevin Carrillo of the Cannabinoid Connect podcast. Watch it here.
What are your options now that the EU has declared CBD from cannabis a narcotic, rather than a Novel Food?
The amount of information that needs to be included in a Novel Food application is quite significant, not to mention the fact that the information contained in a successful Novel Food application must be backed with technical and scientifically certified findings.
If a CBD manufacturer’s application is validated prior to March 31, 2021, its CBD products can be lawfully sold in the UK throughout the whole period of the risk assessment (2-3 years).
Manufacturers of food products containing CBD and other cannabinoid derivatives must submit a Novel Foods application in line with the Novel Foods Regulation in order to sell their products in the European Union.
As a service to our current clients and readers during these difficult times, we are offering a free 20-minute phone call to address your pressing issues – no strings attached.